KMWM
VRTX icon

Keudell/Morrison Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Keudell/Morrison Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Hold
612
– – 0.06% 193
2026
Q1 		$273K Hold
612
– – 0.06% 193
2025
Q4 		$277K Buy
+612
New +$264K 0.06% 187
2025
Q2 		$266K Sell
597
-45
-7% -$20.7K 0.06% 183
2025
Q1 		$311K Sell
642
-4
-0.6% -$1.86K 0.07% 158
2024
Q4 		$260K Hold
646
– – 0.07% 174
2024
Q3 		$300K Sell
646
-285
-31% -$137K 0.08% 161
2024
Q2 		$436K Sell
931
-59
-6% -$25.6K 0.13% 127
2024
Q1 		$414K Sell
990
-10
-1% -$4.23K 0.13% 130
2023
Q4 		$407K Sell
1,000
-50
-5% -$18.5K 0.13% 123
2023
Q3 		$365K Sell
1,050
-47
-4% -$16.4K 0.11% 122
2023
Q2 		$386K Sell
1,097
-118
-10% -$39.8K 0.11% 118
2023
Q1 		$383K Buy
1,215
+123
+11% +$36.9K 0.11% 117
2022
Q4 		$315K Sell
1,092
-117
-10% -$35.7K 0.1% 134
2022
Q3 		$350K Sell
1,209
-143
-11% -$41.1K 0.13% 116
2022
Q2 		$381K Sell
1,352
-86
-6% -$23K 0.14% 113
2022
Q1 		$375K Buy
1,438
+53
+4% +$12.6K 0.16% 126
2021
Q4 		$304K Sell
1,385
-303
-18% -$58.9K 0.12% 139
2021
Q3 		$306K Sell
1,688
-41
-2% -$8.01K 0.13% 134
2021
Q2 		$349K Buy
1,729
+48
+3% +$10K 0.19% 124
2021
Q1 		$361K Buy
1,681
+25
+2% +$5.49K 0.21% 116
2020
Q4 		$391K Buy
1,656
+247
+18% +$56.7K 0.25% 106
2020
Q3 		$383K Buy
1,409
+155
+12% +$42.8K 0.25% 97
2020
Q2 		$364K Buy
1,254
+369
+42% +$100K 0.3% 95
2020
Q1 		$211K Sell
885
-51
-5% -$11.7K 0.21% 122
2019
Q4 		$205K Buy
+936
New +$189K 0.14% 146

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Keudell/Morrison Wealth Management's VRTX Position: Q2 2026 in Review

Keudell/Morrison Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 612 shares worth $304K. The position accounts for 0.06% of the portfolio, ranked #193.

Keudell/Morrison Wealth Management first reported a position in VRTX in Q4 2019 and has held it in 26 quarters since. The position peaked at $436K in Q2 2024. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Keudell/Morrison Wealth Management held 612 shares of Vertex Pharmaceuticals worth $304K as of Q2 2026.
  • Keudell/Morrison Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.06% of Keudell/Morrison Wealth Management's portfolio in Q2 2026, its #193 holding.
  • Keudell/Morrison Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Keudell/Morrison Wealth Management's Vertex Pharmaceuticals position peaked at $436K in Q2 2024.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Keudell/Morrison Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.